ESMO Annual Meeting
October 17 – 21, 2025 | Berlin, Germany

As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access. This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.

Content to be used in accordance with local CPO guidelines

List of Presentations

First-in-human Phase I/Ib Study of the Oral Werner (WRN) Helicase Inhibitor HRO761 in Patients With Microsatellite Instability-high or Mismatch Repair Deficient Advanced Solid Tumors: Interim Safety and Efficacy Analysis From HRO761 Single Agent Dose Escalation

Michael B. Foote, Jian Li, David S. Tan, Aitana Calvo Ferrandiz, Rachel Galot, Tormod Kyrre Guren, Antoine Italiano, Chia-Chi Lin, Arjun Oberoi, Zev A. Wainberg, Jeffrey Yachnin, Timothy A. Yap, Ruben De Kanter, Noemi Di Nanni, Nancy Grande, Aude Izaac, Dragana Jankovic, Laurent Sansregret, Cheng Zhang, Giorgia Clementi, Ankur Nagaraja, Yasutoshi Kuboki

  • Mini Oral Presentation #925MO
    Heidelberg Auditorium - Hall 6.2 | Friday, October 17, 2025 | 16:35-16:40 CEST (Mini Oral) | 16:50-16:55 (Discussion)

This presentation will be available once the congress embargo lifts

A First-in-Human Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumours

Elena Garralda, Marie Florescu, Joachim G Aerts, Tatsuya Yoshida, Sophie Postel-Vinay, Ibiayi Dagogo-Jack, Matthew G. Krebs, Martin Metzenmacher, Thomas John, Hedy Kindler, Mehmet Altan, Lorenz Bankel, Dale R. Shepard, Zev Wainberg, Matteo Duca, Vincent K. Lam, Katelyn Parhiala, Maria-Athina Altzerinakou, Jason Faris, Armando Santoro

  • Proferred Paper/Oral Presentation #919O
    Hanover Auditorium - Hall 7.2c I Sunday, October 19, 2025 | 16:30 – 16:40 CEST (Proffered Paper/Oral Presentation) | 17:00 – 17:10 CEST (Discussion)

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound